Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Nicholls

Showing results (1381-1390 of 1,396) with videos related to

Pageof 140
Sort By:
The New England Journal of Medicine|April 8, 2024
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial InfarctionC Michael Gibson, Danielle Duffy, Serge Korjian, et al.
Atherosclerosis|May 8, 2025
The Brussels International Declaration on Lipoprotein(a) Testing and ManagementFlorian Kronenberg, Nicola Bedlington, Zanfina Ademi, et al.
The New England Journal of Medicine|September 1, 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureMilton Packer, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The New England Journal of Medicine|August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The Lancet Regional Health. Western Pacific|September 11, 2023
Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohortNicholas W S Chew, Bryan Chong, Si Min Kuo, et al.
European Heart Journal|April 15, 2026
Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trialPrashanthan Sanders, Jonathan P Ariyaratnam, Martin K Stiles, et al.
Journal of the American College of Cardiology|April 8, 2024
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MIThomas J Povsic, Serge Korjian, M Cecilia Bahit, et al.
Journal of the American College of Cardiology|September 20, 2023
Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art ReviewGemma A Figtree, Stephen T Vernon, Jason A Harmer, et al.
American Journal of Human Genetics|December 1, 2014
Mutations in GTPBP3 cause a mitochondrial translation defect associated with hypertrophic cardiomyopathy, lactic acidosis, and encephalopathyRobert Kopajtich, Thomas J Nicholls, Joanna Rorbach, et al.
Pageof 140

Showing results (1381-1390 of 1,396) with videos related to

Sort By:
Pageof 140
The New England Journal of Medicine|April 8, 2024
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial InfarctionC Michael Gibson, Danielle Duffy, Serge Korjian, et al.
Atherosclerosis|May 8, 2025
The Brussels International Declaration on Lipoprotein(a) Testing and ManagementFlorian Kronenberg, Nicola Bedlington, Zanfina Ademi, et al.
The New England Journal of Medicine|September 1, 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureMilton Packer, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The New England Journal of Medicine|August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The Lancet Regional Health. Western Pacific|September 11, 2023
Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohortNicholas W S Chew, Bryan Chong, Si Min Kuo, et al.
European Heart Journal|April 15, 2026
Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trialPrashanthan Sanders, Jonathan P Ariyaratnam, Martin K Stiles, et al.
Journal of the American College of Cardiology|April 8, 2024
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MIThomas J Povsic, Serge Korjian, M Cecilia Bahit, et al.
Journal of the American College of Cardiology|September 20, 2023
Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art ReviewGemma A Figtree, Stephen T Vernon, Jason A Harmer, et al.
American Journal of Human Genetics|December 1, 2014
Mutations in GTPBP3 cause a mitochondrial translation defect associated with hypertrophic cardiomyopathy, lactic acidosis, and encephalopathyRobert Kopajtich, Thomas J Nicholls, Joanna Rorbach, et al.
Pageof 140